Pharmaceutical preparations for human use for the treatment of cancer.;
Domain names similar "ENZ"
News around "ENZ" trademark
News sentiment analysis powered by sentiment-insight.com
2023-06-08
neutral
Enzo Biochem, Inc.'s (NYSE:ENZ) Popularity With Investors Is Under Threat From Overpricing
Enzo Biochem, Inc.'s (NYSE:ENZ) price-to-sales (or "P/S") ratio of 1.3x is very similar to the median P/S for the Healthcare industry in the United States. Investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P-S.
2023-03-21
negative
Enzo Biochem: Fiscal Q2 Earnings Snapshot
Enzo Biochem Inc. (ENZ) reported a loss of $11.3 million in its fiscal second quarter. The Farmingdale, New York-based company said it had a lost of 23 cents per share. The life sciences and biotechnology company posted revenue of $16.3million.
Sign Up
